From CFO to CEO: Renee Gala to Lead Jazz Pharmaceuticals Through Next Phase of Growth

Dublin and Palo Alto, CA, July 10, 2025 (PRNewswire) -- In a decisive move underscoring the power of long-range succession planning, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that Renee Gala will succeed Bruce Cozadd as President and Chief Executive Officer, effective August 11, 2025. Gala, currently President and Chief Operating Officer, will also join the Board of Directors at that time. Cozadd, Jazz’s co-founder, Chairperson, and longtime CEO, will step down following a tenure that began with the company’s inception and has been marked by bold transformation and sustained growth. Renee Gala joined Jazz in 2020 as Executive Vice President and Chief Financial Officer, bringing with her a multifaceted background in finance, strategy, and corporate development. She was elevated to President and COO in 2023, assuming responsibility for the company’s global business operations—including R&D, commercialization, technical operations, and quality assurance—at a critical inflection point for the company.

Read full article here.